InvestSMART

Neuren Pharmaceuticals Limited (ASX:NEU)

ALERT: Price-sensitive ASX Announcement for NEU
Current share price for NEU : $16.460 -3.47 (-17.41%)+
Announcement
Release
14 Jan 2026 10:26AM
Price at Release
$19.930
Full Release
download
Summary
Neuren Pharmaceuticals Limited announced that its partner, Acadia Pharmaceuticals, projected global net sales for DAYBUE to reach approximately US$700 million by 2028. This growth is driven by the introduction of DAYBUE STIX, expansion of US customer-facing teams, and international expansion with anticipated European approval. Since its 2023 US launch, DAYBUE has treated over 2,000 Rett syndrome patients. The DAYBUE oral solution was approved in Israel, and a Phase 3 trial in Japan is underway. Neuren develops therapies for serious neurological disorders, with trofinetide approved by the US FDA for Rett syndrome and another candidate, NNZ-2591, in development for other disorders.
Key Points
  • DAYBUE global net sales projected to reach ~US$700m in 2028
  • More than 2,000 Rett patients treated since US launch in 2023
  • DAYBUE STIX US launch in Q1 2026, full launch by Q2 2026
  • DAYBUE oral solution approved in Israel
  • Phase 3 trial of trofinetide in Japan with results expected Q4 2026/Q1 2027
  • Neuren's focus on therapies for serious neurological disorders
  • Exclusive worldwide license granted to Acadia for trofinetide
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.